Endometrioma Detected on Recombinant TSH-Stimulated 18F-FDG-PET/CT

Case Report

Austin J Endocrinol Diabetes. 2023; 10(1): 1100.

Endometrioma Detected on Recombinant TSH-Stimulated 18F-FDG-PET/CT

Tamayo-Carabaño D*; Martínez-Diher L

Department of Nuclear Medicine, Universitary Hospital Fundación Jiménez Díaz, Spain

*Corresponding author: Tamayo-Carabaño Daniella. Department of Nuclear Medicine, Universitary Hospital Fundación Jiménez Díaz, Avda. de los Reyes Católicos, 2, 28040 Madrid, Spain. Tel: +34 915504898 Email: dratamayoc@gmail.com

Received: July 17, 2023 Accepted: August 15, 2023 Published: August 22, 2023

Abstract

A 43-year-old female patient diagnosed with high-grade follicular thyroid neoplasm in October 2022, treated with total thyroidectomy + left laterocervical lymphadenectomy in February 2023 with stage T4N0M0. A study with 18F-FDG PET/CT stimulated with Recombinant Thyroid-Stimulating Hormone (rTSH) was requested prior to performing ablative treatment with radioactive iodine (131I) on the same day. Two days prior to the PET/CT study, a subcutaneous injection of rTSH (Thyrogen®) was administered, presenting, immediately after, pain in the right iliac fossa that did not subside with anti-inflammatories. The PET/CT image shows tumor remains in the anterior cervical region and a pelvic mass dependent on the right adnexa, not previously known, of a cystic nature, septated with FDG uptake, with an SUVmax of 15,3, which partially compresses the ipsilateral ureter. Treatment with 131I was postponed due to acute abdominal pain and it was decided to take him to the operating room where an oopherectomy + right adnexectomy was performed with an anatomopathological result of endometrioid cystadenoma. Due to structural similarities and cross-reactivity between hormones, and the presence of TSH receptors in endometrioid tissue, we propose that the growth of the tumor lesion in this case was precipitated by rTSH administration.

Keywords: 18F-FDG PET/CT; Endometrioma; Recombinant thyroid-stimulating hormone; rTSH; TSH receptors; Thyrogen®

Case Presentation

We present the case of a 43-year-old female patient diagnosed with high-grade follicular thyroid neoplasm in October 2022, who was treated with total thyroidectomy and left laterocervical lymphadenectomy in February 2023 with stage T4N0M0. It was decided to perform ablation of thyroid remnants with radioactive iodine (131I), previously requesting an extension study with 18F-FDG PET/CT the same day. The treatment preparation with 131I would be stimulated with Recombinant Thyroid-Stimulating Hormone (rTSH) administered two days before a daily subcutaneous injection of rTSH (Thyrogen®), which would be used to perform the PET/CT study under the same stimulation.

Immediately after the administration of the injections, the patient began with acute pain in the right iliac fossa that did not subside with anti-inflammatories, and radiated to the ipsilateral flank with positive fist percussion.

The acquisition of the 18F-FDG PET/CT study was performed, showing hyper-uptake foci in the anterior cervical region compatible with thyroid remnants; and a pelvic mass of 9 cm in diameter, dependent on the right adnexus, not previously known, of a cystic nature, septated, with FDG uptake, with an SUVmax of 15,3, partially compressing the ipsilateral ureter. These findings are reported as a pelvic mass suggestive of malignancy given its morphometabolic characteristics (Figure 1).

Citation: Tamayo-Carabaño D, Martínez-Diher L. Endometrioma Detected on Recombinant TSH-Stimulated 18F-FDG-PET/CT. Austin J Endocrinol Diabetes. 2023; 10(1): 1100.